%0 Journal Article
%T A strategic approach towards mass balance investigations in pharmaceutical drug substance release testing: A peculiar out of specification case study encountered during API manufacture.
%A Scott BS
%A Zhang K
%A Yehl PM
%A Yang SH
%J J Pharm Biomed Anal
%V 238
%N 0
%D 2024 Jan 20
%M 37866077
%F 3.571
%R 10.1016/j.jpba.2023.115773
%X Mass balance in drug substances release testing is a critical quality attribute in pharmaceutical manufacturing that continues to challenge modern analytical characterization. This specific perspective of mass balance is lacking in literature, and the following work addresses the knowledge gap related to this topic by examining an in-depth case study and detailing the systematic investigation into mass imbalance observed during release testing of a small molecule API. The process followed a logical stepwise progression beginning with most probable causes and expanded to more obscure causes that require a deeper examination of the API in question until the undetected impurity in question was finally identified. The discovered impurity was eventually found to be formed from a unique side reaction that led to the formation of API-related oligomer impurities, which had eluded conventional small molecule release testing strategies. Ultimately, the characterization gap was traced back to deficiency in the LC results of the developed API purity methods. More importantly, this gap provides an ideal opportunity to highlight common oversights and pitfalls encountered in early phase pharmaceutical development especially as it relates to the method development of truly representative chromatography methods in the API characterization. The work reflects on the key lessons learned from the highlighted pitfalls that were encountered in this case study and offers strategic insights to guide and to improve the development workflow for drug substance characterization strategies.